Interferon-β sensitizes human malignant melanoma cells to temozolomide-induced apoptosis and autophagy

Kotaro Makita, Hiroyuki Hara, Emiko Sano, Yutaka Okamoto, Yushi Ochiai, Tomonori Harada, Takuya Ueda, Tomohiro Nakayama, Shin Aizawa, Atsuo Yoshino

Research output: Contribution to journalArticle

Abstract

Malignant melanoma is a highly aggressive skin cancer that is highly resistant to chemotherapy. Adjuvant therapy is administered to patients with melanoma that possess no microscopic metastases or have a high risk of developing microscopic metastases. Methylating agents, including dacarbazine (DTIC) and temozolomide (TMZ), pegylated interferon (IFN)-α2b and interleukin-2 have been approved for adjuvant immuno-chemotherapy; however, unsatisfactory results have been reported following the administration of methylating agents. IFN-β has been considered to be a signaling molecule with an important therapeutic potential in cancer. The aim of the present study was to elucidate whether antitumor effects could be augmented by the combination of TMZ and IFN-β in malignant melanoma. We evaluated the efficacy of TMZ and IFN-β by comparing O 6 -methylguanine-DNA transferase (MGMT)-proficient and -deficient cells, as MGMT has been reported to be associated with the resistance to methylating agents. Cell viability was determined by counting living cells with a Coulter counter, and apoptosis was analyzed by dual staining with Annexin V Alexa FluorR 488 and propidium iodide. The expression of proteins involved in the cell cycle, apoptosis and autophagy was evaluated by western blot analysis. The combined treatment with TMZ and IFN-β suppressed cell proliferation and induced cell cycle arrest. We also demonstrated that a combination of TMZ and IFN-β enhanced apoptosis and autophagy more efficiently compared with TMZ treatment alone. These findings suggest that antitumor activity may be potentiated by IFN-β in combination with TMZ.

Original languageEnglish
Pages (from-to)1864-1874
Number of pages11
JournalInternational journal of oncology
Volume54
Issue number5
DOIs
Publication statusPublished - 2019 Apr 1
Externally publishedYes

Fingerprint

temozolomide
Autophagy
Interferons
Melanoma
Apoptosis
Dacarbazine
Neoplasm Metastasis
Propidium
Annexin A5
Skin Neoplasms
Therapeutics
Adjuvant Chemotherapy
Transferases
Cell Cycle Checkpoints
Interleukin-2
Cell Survival
Cell Cycle

Keywords

  • Apoptosis
  • Autophagy
  • Human interferon-β
  • Malignant melanoma
  • MGMT
  • Temozolomide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Interferon-β sensitizes human malignant melanoma cells to temozolomide-induced apoptosis and autophagy. / Makita, Kotaro; Hara, Hiroyuki; Sano, Emiko; Okamoto, Yutaka; Ochiai, Yushi; Harada, Tomonori; Ueda, Takuya; Nakayama, Tomohiro; Aizawa, Shin; Yoshino, Atsuo.

In: International journal of oncology, Vol. 54, No. 5, 01.04.2019, p. 1864-1874.

Research output: Contribution to journalArticle

Makita, K, Hara, H, Sano, E, Okamoto, Y, Ochiai, Y, Harada, T, Ueda, T, Nakayama, T, Aizawa, S & Yoshino, A 2019, 'Interferon-β sensitizes human malignant melanoma cells to temozolomide-induced apoptosis and autophagy', International journal of oncology, vol. 54, no. 5, pp. 1864-1874. https://doi.org/10.3892/ijo.2019.4743
Makita, Kotaro ; Hara, Hiroyuki ; Sano, Emiko ; Okamoto, Yutaka ; Ochiai, Yushi ; Harada, Tomonori ; Ueda, Takuya ; Nakayama, Tomohiro ; Aizawa, Shin ; Yoshino, Atsuo. / Interferon-β sensitizes human malignant melanoma cells to temozolomide-induced apoptosis and autophagy. In: International journal of oncology. 2019 ; Vol. 54, No. 5. pp. 1864-1874.
@article{13f9fe04caef406fa310cc67f4a7b3b8,
title = "Interferon-β sensitizes human malignant melanoma cells to temozolomide-induced apoptosis and autophagy",
abstract = "Malignant melanoma is a highly aggressive skin cancer that is highly resistant to chemotherapy. Adjuvant therapy is administered to patients with melanoma that possess no microscopic metastases or have a high risk of developing microscopic metastases. Methylating agents, including dacarbazine (DTIC) and temozolomide (TMZ), pegylated interferon (IFN)-α2b and interleukin-2 have been approved for adjuvant immuno-chemotherapy; however, unsatisfactory results have been reported following the administration of methylating agents. IFN-β has been considered to be a signaling molecule with an important therapeutic potential in cancer. The aim of the present study was to elucidate whether antitumor effects could be augmented by the combination of TMZ and IFN-β in malignant melanoma. We evaluated the efficacy of TMZ and IFN-β by comparing O 6 -methylguanine-DNA transferase (MGMT)-proficient and -deficient cells, as MGMT has been reported to be associated with the resistance to methylating agents. Cell viability was determined by counting living cells with a Coulter counter, and apoptosis was analyzed by dual staining with Annexin V Alexa FluorR 488 and propidium iodide. The expression of proteins involved in the cell cycle, apoptosis and autophagy was evaluated by western blot analysis. The combined treatment with TMZ and IFN-β suppressed cell proliferation and induced cell cycle arrest. We also demonstrated that a combination of TMZ and IFN-β enhanced apoptosis and autophagy more efficiently compared with TMZ treatment alone. These findings suggest that antitumor activity may be potentiated by IFN-β in combination with TMZ.",
keywords = "Apoptosis, Autophagy, Human interferon-β, Malignant melanoma, MGMT, Temozolomide",
author = "Kotaro Makita and Hiroyuki Hara and Emiko Sano and Yutaka Okamoto and Yushi Ochiai and Tomonori Harada and Takuya Ueda and Tomohiro Nakayama and Shin Aizawa and Atsuo Yoshino",
year = "2019",
month = "4",
day = "1",
doi = "10.3892/ijo.2019.4743",
language = "English",
volume = "54",
pages = "1864--1874",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Interferon-β sensitizes human malignant melanoma cells to temozolomide-induced apoptosis and autophagy

AU - Makita, Kotaro

AU - Hara, Hiroyuki

AU - Sano, Emiko

AU - Okamoto, Yutaka

AU - Ochiai, Yushi

AU - Harada, Tomonori

AU - Ueda, Takuya

AU - Nakayama, Tomohiro

AU - Aizawa, Shin

AU - Yoshino, Atsuo

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Malignant melanoma is a highly aggressive skin cancer that is highly resistant to chemotherapy. Adjuvant therapy is administered to patients with melanoma that possess no microscopic metastases or have a high risk of developing microscopic metastases. Methylating agents, including dacarbazine (DTIC) and temozolomide (TMZ), pegylated interferon (IFN)-α2b and interleukin-2 have been approved for adjuvant immuno-chemotherapy; however, unsatisfactory results have been reported following the administration of methylating agents. IFN-β has been considered to be a signaling molecule with an important therapeutic potential in cancer. The aim of the present study was to elucidate whether antitumor effects could be augmented by the combination of TMZ and IFN-β in malignant melanoma. We evaluated the efficacy of TMZ and IFN-β by comparing O 6 -methylguanine-DNA transferase (MGMT)-proficient and -deficient cells, as MGMT has been reported to be associated with the resistance to methylating agents. Cell viability was determined by counting living cells with a Coulter counter, and apoptosis was analyzed by dual staining with Annexin V Alexa FluorR 488 and propidium iodide. The expression of proteins involved in the cell cycle, apoptosis and autophagy was evaluated by western blot analysis. The combined treatment with TMZ and IFN-β suppressed cell proliferation and induced cell cycle arrest. We also demonstrated that a combination of TMZ and IFN-β enhanced apoptosis and autophagy more efficiently compared with TMZ treatment alone. These findings suggest that antitumor activity may be potentiated by IFN-β in combination with TMZ.

AB - Malignant melanoma is a highly aggressive skin cancer that is highly resistant to chemotherapy. Adjuvant therapy is administered to patients with melanoma that possess no microscopic metastases or have a high risk of developing microscopic metastases. Methylating agents, including dacarbazine (DTIC) and temozolomide (TMZ), pegylated interferon (IFN)-α2b and interleukin-2 have been approved for adjuvant immuno-chemotherapy; however, unsatisfactory results have been reported following the administration of methylating agents. IFN-β has been considered to be a signaling molecule with an important therapeutic potential in cancer. The aim of the present study was to elucidate whether antitumor effects could be augmented by the combination of TMZ and IFN-β in malignant melanoma. We evaluated the efficacy of TMZ and IFN-β by comparing O 6 -methylguanine-DNA transferase (MGMT)-proficient and -deficient cells, as MGMT has been reported to be associated with the resistance to methylating agents. Cell viability was determined by counting living cells with a Coulter counter, and apoptosis was analyzed by dual staining with Annexin V Alexa FluorR 488 and propidium iodide. The expression of proteins involved in the cell cycle, apoptosis and autophagy was evaluated by western blot analysis. The combined treatment with TMZ and IFN-β suppressed cell proliferation and induced cell cycle arrest. We also demonstrated that a combination of TMZ and IFN-β enhanced apoptosis and autophagy more efficiently compared with TMZ treatment alone. These findings suggest that antitumor activity may be potentiated by IFN-β in combination with TMZ.

KW - Apoptosis

KW - Autophagy

KW - Human interferon-β

KW - Malignant melanoma

KW - MGMT

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=85063509194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063509194&partnerID=8YFLogxK

U2 - 10.3892/ijo.2019.4743

DO - 10.3892/ijo.2019.4743

M3 - Article

C2 - 30864696

AN - SCOPUS:85063509194

VL - 54

SP - 1864

EP - 1874

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -